EMERALD-1: durvalumab with or without bevacizumab added to transarterial chemoembolisation for embolisation-eligible hepatocellular carcinoma
Adding durvalumab and bevacizumab to chemoembolisation lengthened the time to progression by about seven months in liver cancer suitable for embolisation, the first systemic combination to improve on chemoembolisation alone.
Overview
Phase 3 placebo-controlled trial of 616 patients with unresectable hepatocellular carcinoma eligible for embolisation randomised to transarterial chemoembolisation with durvalumab plus bevacizumab, durvalumab alone, or placebo.
Median progression-free survival was 15.0 months with durvalumab plus bevacizumab against 8.2 months with placebo (hazard ratio 0.77), while durvalumab alone did not significantly improve progression-free survival; grade 3 to 4 adverse events were more frequent with the combination.
- Median progression-free survival 15.0 vs 8.2 months; hazard ratio 0.77.
- Durvalumab alone with chemoembolisation: 10.0 months (not significant).
Chemoembolisation combined with durvalumab and bevacizumab is a new option for intermediate-stage hepatocellular carcinoma where approved, though overall survival benefit is not yet shown.
- Overall survival data immature.
- Bleeding risk with bevacizumab requires endoscopic assessment.
Similar pages
not linked directly; found by shared links- Key paperArterial embolisation or chemoembolisation versus symptomatic treatment in unresectable hepatocellular carcinoma
Shares Intermediate hepatocellular carcinoma (BCLC B), The Lancet.
- Key paperLEAP-012: transarterial chemoembolisation with lenvatinib plus pembrolizumab versus placebo for unresectable non-metastatic hepatocellular carcinoma
Shares Intermediate hepatocellular carcinoma (BCLC B), The Lancet.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Durvalumab, Bevacizumab.
- PairingTACE + immunotherapy/anti-VEGF
Shares EMERALD-1, Intermediate hepatocellular carcinoma (BCLC B).
- TermTACE (transarterial chemoembolisation)
Shares EMERALD-1, Intermediate hepatocellular carcinoma (BCLC B).
- TrialAssess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
Shares Durvalumab, Bevacizumab.
- Key paperIMbrave050: adjuvant atezolizumab plus bevacizumab versus active surveillance after resection or ablation of high-risk hepatocellular carcinoma
Shares The Lancet, Bevacizumab.
- TrialA Study of Durvalumab or Tremelimumab Monotherapy, or Durvalumab in Combination With Tremelimumab or Bevacizumab in Advanced Hepatocellular Carcinoma
Shares Durvalumab, Bevacizumab.